Roughly one-quarter of all Americans – an estimated 100 million adults and children – have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure. Combining a diverse array of basic science, biomarkers, imaging and clinical efforts, University of California, San Diego School of Medicine has launched a new NAFLD Research Center to better understand the disease and develop treatments where none currently exist.
“We already have a lot of depth and breadth in the study and treatment of NAFLD and associated conditions at UC San Diego,” said Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology and director of the new center. … Read the full story from the UC San Diego Newsroom
NAFLD Research Center director Rohit Loomba, MD, MHSc, is Professor of Clinical Medicine and Associate Director of Clinical Research in the Division of Gastroenterology and Hepatology.
He is a clinical and translational physician-scientist who focuses his work on chronic liver diseases with particular attention to nonalcoholic fatty liver disease (NAFLD). He is an internationally recognized expert in translational research and innovative clinical trial design in NAFLD and nonalcoholic steatohepatitis (NASH) and hepatic fibrosis.
He directs the NAFLD Clinic at UC San Diego Medical Center.
Dr. Loomba became a member of the Division of Gastroenterology faculty in 2009, when he graduated from the UC San Diego Gastroenterology Fellowship Program. He received his clinical and research training in advanced hepatology at the National Institutes of Health.
He holds an adjunct faculty appointment in the UC San Diego Division of Epidemiology, Department of Family Medicine and Public Health at UC San Diego.